Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-A00468-35 | Other Identifier | France : ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| URC-CIC Paris Descartes Necker Cochin | OTHER |
Not provided
Not provided
Not provided
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.
The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Juvenile Idiopathic Arthritis | Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sample | Biological | Addtional tube of blood needed for follow up of patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Dosage of angiogenic markers | Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. | 5 years |
| Dosage of angiogenic markers | Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. | 5 years |
| Dosage of inflammatory markers by ELISA method | Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. | 5 years |
| Dosage of inflammatory markers by ELISA method | Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Questionnaires | Severity of JIA | 5 years |
| Collection of treatments received | Severity of JIA | 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients over (or egal) 16 years old with diagnosis of Juvenile Idiopathic Arthritis starting their follow up in adult rheumatology ward in Cochin hospital
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yannick ALLANORE, PD, PhD | Contact | 0033158412563 | yannick.allanore@aphp.fr | |
| Marie BENHAMMANI-GODARD | Contact | +33 1 58411190 | marie.godard@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Yannick ALLANORE, PD, PhD | Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rheumatology Department, Cochin Hospital | Recruiting | Paris | IDF | 75014 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001171 | Arthritis, Juvenile |
| C564597 | Cone-Rod Dystrophy 10 |
| C565158 | Cornea Plana 1 |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| D000069237 | Arthrocentesis |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
| Joint puncture | Biological | Joint puncture if needed according to routine care of the patients |
|
| Structural damage determined by x-rays | Structural damage determined by x-rays during follow up. | 5 years |
| Angiogenic biomarkers | Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA. | At inclusion |
| Inflammatory biomarkers | Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA. | At inclusion |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
| D019152 | Paracentesis |
| D013812 | Therapeutics |